In vitro studies, undertaken by two leading microbiology centers, confirm RHB-204's killing capability on Mycobacterium avium subspecies paratuberculosis (MAP) and its MAP-killing comparability to RedHill's
TEL AVIV, Israel and RALEIGH, N.C., Oct. 19, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its
SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- USA Newsroom News Commentary - This has been a week of slow leaks rather than blowouts for U.S. stocks. As of midday Thursday, the Dow Jones Industrial Average, the
Stock Preachers News CommentaryNEW YORK, Oct. 1, 2026 /CNW/ -- Stocks closed out a choppy week on the back foot, with the Dow shedding nearly 2% and small caps underperforming as the Russell 2000 fell more than 1% on
Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota® and Clenpiq®, two established FDA-approved gastrointestinal (GI) brands that generated $37.5 million in 2025 net
Together with the previously announced Talicia® strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that
Together with the previously announced Talicia strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that
Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated path toward
The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths--Finalization of development next steps and potential partnership discussions ongoing, including with the
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrantsTEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ -- RedHill Biopharma
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrantsTEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- RedHill Biopharma
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young children--Rare
RALEIGH, N.C. and TEL-AVIV, Israel, June 8, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential
RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-1042, designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium avium subspecies
